Secondary 12-Month Ocular Outcomes of a Phase 1 Dosing Study of Bevacizumab for Retinopathy of Prematurity. - Crouch ER; Kraker RT; Wallace DK; Holmes JM; Repka MX; Collinge JE; Bremer DL; Gray ME; Smith HA; Steinkuller PG (JAMA ophthalmology, 2020)